Last reviewed · How we verify
Medicinal air
Medicinal air is a Inhalation gas therapy Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Hypoxemia requiring supplemental oxygen therapy, Respiratory insufficiency in hospitalized patients.
Medicinal air delivers therapeutic oxygen and/or other gaseous components to improve oxygenation and respiratory function in patients with hypoxemia or respiratory compromise.
Medicinal air is a traditional medicinal product derived from Argan spinosa oil, and it has been studied in various clinical trials for conditions such as Type 2 Diabetes Mellitus and loneliness. The exact mechanism of action of medicinal air is unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Medicinal air |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Inhalation gas therapy |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Critical Care |
| Phase | Phase 3 |
Mechanism of action
Medicinal air is a pharmaceutical-grade gaseous preparation used to increase arterial oxygen saturation and improve tissue oxygenation in patients with inadequate oxygen levels. It may contain oxygen, nitrogen, and other inert gases in controlled proportions, administered via inhalation to restore normal blood gas parameters and support respiratory physiology.
Approved indications
- Hypoxemia requiring supplemental oxygen therapy
- Respiratory insufficiency in hospitalized patients
Common side effects
- Oxygen toxicity (with prolonged high-concentration exposure)
- Drying of respiratory mucosa
- Discomfort from delivery apparatus
Key clinical trials
- Self-hangIng Patient and Hyperbaric Oxygen Therapy _ SIPHON Study (PHASE4)
- Effect of Oxygen Administration in the Non-dependent Lung on Postoperative Complications After Lung Surgery (PHASE4)
- The Effect of Horticultural Therapy on Loneliness and Life Satisfaction in Elderly Adults Living in Nursing Home (NA)
- Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia (NA)
- MEOPA to Improve Physical Therapy Results After Multilevel Surgery (PHASE3)
- Carbon Dioxide Versus Iodine Contrast for Endovascular Revascularization of Aortoiliac Occlusive Disease (NA)
- Effects of Argan Spinosa Oil in the Treatment of Diaper Dermatitis in Infants and Toddlers (NA)
- Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Medicinal air CI brief — competitive landscape report
- Medicinal air updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Medicinal air
What is Medicinal air?
How does Medicinal air work?
What is Medicinal air used for?
Who makes Medicinal air?
What drug class is Medicinal air in?
What development phase is Medicinal air in?
What are the side effects of Medicinal air?
Related
- Drug class: All Inhalation gas therapy drugs
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Respiratory / Critical Care
- Indication: Drugs for Hypoxemia requiring supplemental oxygen therapy
- Indication: Drugs for Respiratory insufficiency in hospitalized patients
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing